BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes In a poster presentation on Thursday, Dec. 7th at 6:30pm and an oral

BMEA

News

Basilea Announces Milestone as Cresemba (Isavuconazole) Sales in Asia Pacific and China Trigger Additional $1.25M Payment from Pfizer

By Benzinga Newsdesk

November 20, 3:25 AM

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued

PFE

Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday

By Lisa Levin

November 10, 11:50 AM

U.S. stocks traded higher, with the Nasdaq surging more than 500 points on Thursday. Here are some big stocks recording losses in today’s session.

ADV

Raymond James Downgrades Upland Software to Market Perform

Related Posts

Morgan Stanley Maintains Equal-Weight on Seagate Tech Hldgs, Lowers Price Target to $89

Biomea Fusion To Present Long-Term Follow-Up Data From Ongoing Phase II Study Of BMF-219 In Adults With Type 2 Diabetes And Results From Ex-Vivo Human Islet Experiments At The World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

Basilea Announces Milestone as Cresemba (Isavuconazole) Sales in Asia Pacific and China Trigger Additional $1.25M Payment from Pfizer

Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday